Browse by Aston Author

Article

Wilding, J.P.H.; Bailey, C.J.; Rigney, U.; Blak, B.; Beekman, W. and Emmas, C.E. (2015). Changes in HbA1c and weight in type 2 diabetes patients initiating dapagliflozin treatment in routine UK primary care. Diabetologia, 58 (Suppl.), S352-S356.

Bailey, C.J. (2015). Safety of antidiabetes medications:an update. Clinical pharmacology and therapeutics, 98 (2), 185–195.

Bailey, C.J. (2015). The current drug treatment landscape for diabetes and perspectives for the future. Clinical pharmacology and therapeutics, 98 (2), 170–184.

Bailey, C.J.; Berria, R.; Stager, W.; Gautier, J.-F.; Aronson, R. and Ahrén, B. (2013). Consistent reduction of postprandial glucagon and insulin by lixisenatide in the GetGoal clinical trial programme. Diabetologia, 56 (Suppl.), S403.

Bailey, C.J.; Iqbal, N.; T'joen, C. and List, J.F. (2012). Dapagliflozin monotherapy in drug-naïve patients with diabetes:a randomized-controlled trial of low-dose range. Diabetes, Obesity and Metabolism, 14 (10), pp. 951-959.

Pararasa, C.; Gao, D.; Dunston, C.R.; Bailey, C.J. and Griffiths, H.R. (2012). Palmitate induces phenotype changes in monocytes via de novo ceramide synthesis. Free Radical Biology and Medicine, 53 (Supple), S136.

Paget, M.B.; Murray, H.E.; Bailey, C.J.; Flatt, P.R. and Downing, R. (2011). Rotational co-culture of clonal β-cells with endothelial cells:effect of PPAR-γ agonism in vitro on insulin and VEGF secretion. Diabetes, Obesity and Metabolism, 13 (7), pp. 662-668.

Irwin, N.; McKinney, J.M.; Bailey, C.J.; McClenaghan, N.H. and Flatt, P.R. (2011). Acute and long-term effects of peroxisome proliferator-activated receptor-γ activation on the function and insulin secretory responsiveness of clonal beta-cells. Hormone and Metabolic Research, 43 (4), pp. 244-249.

Bailey, C.J. and Kodack, M. (2011). Patient adherence to medication requirements for therapy of type 2 diabetes. International Journal of Clinical Practice, 65 (3), pp. 314-322.

Alberti, K.G.M.M.; Bailey, C.J.; Blonde, L.; Felton, A.M.; Zimmet, P. and , and on behalf of the Global Partnership for Effective Diabetes M (2007). Partnering with governments and other institutions:driving change in diabetes care. International Journal of Clinical Practice, 61 (Suppl.), pp. 38-46.

Richardson, D.K.; Jones, R.B. and Bailey, C.J. (2006). The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes. Hormone and Metabolic Research, 38 (11), pp. 727-731.

Bailey, C.J. (2006). Fenofibrate and cardiovascular risk:a synopsis and commentary on (FIELD). Diabetic Medicine, 23 (2), pp. 109-112.

Green, B.D.; Gault, V.A.; Mooney, M.H.; Irwin, N.; Bailey, C.J.; Harriott, P.; Greer, B.; Flatt, P.R. and O'Harte, F.P.M. (2003). Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. Journal of Molecular Endocrinology, 31 (3), pp. 529-540.

Rana, K.; Hill, E.J.; Bailey, C.J.; Bellary, S. and Brown, J.E. Association between body composition, circulating irisin and telomere length in healthy individuals and individuals with Type 2 diabetes. Diabetic Medicine, 31 (s1), p. 38.

Holt, R.I.G.; Barnett, A.H. and Bailey, C.J. Bromocriptine:old drug, new formulation and new indication. Diabetes, Obesity and Metabolism, 12 (12), pp. 1048-1057.

Green, B.D.; Gault, V.A.; Mooney, M.H.; Irwin, N.; Harriott, P.; Greer, B.; Bailey, C.J.; O'Harte, F.P.M. and Flatt, P.R. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. Biological Chemistry, 385 (2), pp. 169-177.

Irwin, N.; McKinney, J.M.; Bailey, C.J.; Flatt, P.R. and McClenaghan, N.H. Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas. Diabetes, Obesity and Metabolism, 12 (12), pp. 1066-1071.

Bailey, C.J.; Morales Villegas, E.C.; Woo, V.; Tang, W.; Ptaszynska, A. and List, J.F. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes:a randomized double-blind placebo-controlled 102-week trial. Diabetic Medicine, 32 (4), pp. 531-541.

Bailey, C.J. and Day, C. Fixed-dose single tablet antidiabetic combinations. Diabetes, Obesity and Metabolism, 11 (6), pp. 527-533.

Bailey, C.J. and Turner, S.L. Glucosamine-induced insulin resistance in L6 muscle cells. Diabetes, Obesity and Metabolism, 6 (4), pp. 293-298.

Green, B.D.; Mooney, M.H.; Gault, V.A.; Irwin, N.; Bailey, C.J.; Harriott, P.; Greer, B.; Flatt, P.R. and O'Harte, F.P.M. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism, 53 (2), pp. 252-259.

Bailey, C.J.; Wilcock, C. and Scarpello, J.H.B. Metformin and the intestine. Diabetologia, 51 (8), pp. 1552-1553.

Bailey, C.J. and Day, C. Metformin:its botanical background. Practical Diabetes International, 21 (3), pp. 115-117.

Green, B.D.; Mooney, M.H.; Gault, V.A.; Irwin, N.; Bailey, C.J.; Harriott, P.; Greer, B.; O'Harte, F.P.M. and Flatt, P.R. N-terminal His7-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. Journal of Endocrinology, 180 (3), pp. 379-388.

Choudry, N.; Robinson, J.; Arif, M.; Rana, K.S.; Hill, E.J.; Turner, S.; Bailey, C.J. and Brown, J.E. Phytoestrogen-ind uced glucose uptake and cellular proliferation in L6 myotubesadipocyte function. Diabetic Medicine, 30 (S1), p. 39.

Ahrén, B.; Gautier, J.-F.; Berria, R.; Stager, W.; Aronson, R. and Bailey, C.J. Pronounced reduction of postprandial glucagon by lixisenatide:a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 16 (9), pp. 861-868.

Flatt, P.R.; Bailey, C.J. and Green, B.D. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Current Drug Metabolism, 10 (2), pp. 125-137.

Bailey, C.J.; Gross, J.L.; Yadav, M.; Iqbal, N.; Mansfield, T.A. and List, J.F. Sustained efficacy of dapagliflozin when added to metformin in type 2 diabetes inadequately controlled by metformin monotherapy. Diabetologia, 54 (S1), S67.

Bailey, C.J.; Wilding, J.; Nauck, M.A.; Ferranninin, E.; Ptaszynska, A.A.; Apanovitch, A.M.; Sugg, J. and Parikh, S.J. Sustained reductions in weight and HbA1c with dapagliflozin: long-term results from phase III clinical studies in type 2 diabetes. Diabetologia, 55 (Suppl.), S295.

Home, P.D.; Bailey, C.J.; Donaldson, J.; Chen, H. and Stewart, M.W. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes. Diabetic Medicine, 24 (6), pp. 618-625.